Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Blood (2021) 137 (16): 2231–2242.

https://doi.org/10.1182/blood.2020009217

Published: 2021

Includes: Supplemental data

Journal Articles

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

Guy Young, Ri Liesner, Tiffany Chang, Robert Sidonio, Jr, Johannes Oldenburg, Victor Jiménez-Yuste, Johnny Mahlangu, Rebecca Kruse-Jarres, Michael Wang, Marianne Uguen, Michelle Y. Doral, Lilyan Y. Wright, Christophe Schmitt, Gallia G. Levy, Midori Shima, Maria Elisa Mancuso

Blood (2019) 134 (24): 2127–2138.

https://doi.org/10.1182/blood.2019001869

Published: 2019

Includes: Supplemental data

Journal Articles

Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3

Anna Kiialainen, PhD, Markus Niggli, PhD, Christine L. Kempton, MD MSc, Giancarlo Castaman, MD, Tiffany Y. Chang, MD MAS, Ido Paz-Priel, MD, Joanne I Adamkewicz, PhD, Gallia G. Levy, MD PhD

Blood (2019) 134 (Supplement_1): 626.

https://doi.org/10.1182/blood-2019-123689

Published: 2019

Journal Articles

Untreated Bleeds May Be Historically Under-Reported and More Prevalent in People with Hemophilia A with Inhibitors: An Examination of Bleed Data from a Prospective, Non-Interventional Study

Michael U. Callaghan, MD, Elina Asikanius, Michaela Lehle, Johannes Oldenburg, Johnny Mahlangu, Marianne Uguen, Sammy Chebon, Rebecca Kruse-Jarres, Victor Jimenez-Yuste, Midori Shima, MD PhD, Peter Trask, Christine L. Kempton, Craig M. Kessler, Gallia G. Levy, Elena Santagostino

Blood (2018) 132 (Supplement 1): 383.

https://doi.org/10.1182/blood-2018-99-118160

Published: 2018

Journal Articles

Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia Α with Inhibitors: Results from the HAVEN 2 Study

Guy Young, Ri Liesner, Robert F. Sidonio, Jr., Johannes Oldenburg, Victor Jimenez-Yuste, Johnny Mahlangu, Rebecca Kruse-Jarres, Michael Wang, Tiffany Chang, Marianne Uguen, Michelle Doral, Christophe Schmitt, Gallia G. Levy, Midori Shima, MD PhD, Maria Elisa Mancuso

Blood (2018) 132 (Supplement 1): 632.

https://doi.org/10.1182/blood-2018-99-118153

Published: 2018

Journal Articles

HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors

Guy Young, Robert F. Sidonio, Ri Liesner, Johannes Oldenburg, Tiffany Chang, Marianne Uguen, Christophe Dhalluin, Christophe Schmitt, Gallia G. Levy, Midori Shima, MDPhD, Johnny Mahlangu

Blood (2017) 130 (Supplement 1): 85.

https://doi.org/10.1182/blood.V130.Suppl_1.85.85

Published: 2017

Journal Articles

Emicizumab Subcutaneous Dosing Every 4 Weeks for the Management of Hemophilia A: Preliminary Data from the Pharmacokinetic Run-in Cohort of a Multicenter, Open-Label, Phase 3 Study (HAVEN 4)

Victor Jimenez-Yuste, Midori Shima, MDPhD, Katsuyuki Fukutake, Michaela Lehle, Sammy Chebon, Sylvie Retout, Agnès Portron, Gallia G. Levy

Blood (2017) 130 (Supplement 1): 86.

https://doi.org/10.1182/blood.V130.Suppl_1.86.86

Published: 2017

Journal Articles

Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study

Maria Elisa Mancuso, Michael U. Callaghan, Rebecca Kruse-Jarres, Christine L Kempton, Jin Xu, Olivier Catalani, Elina Asikanius, Gallia G. Levy, Midori Shima, MDPhD, Guy Young, Johannes Oldenburg

Blood (2017) 130 (Supplement 1): 1071.

https://doi.org/10.1182/blood.V130.Suppl_1.1071.1071

Published: 2017

Journal Articles

Bleeding Events and Safety Outcomes in Pediatric Persons with Hemophilia A with Inhibitors: The First Non-Interventional Study (NIS) from a Real-World Setting

Johannes Oldenburg, Midori Shima, MDPhD, Rebecca Kruse-Jarres, Elena Santagostino, Johnny Mahlangu, Nives Selak Bienz, Sammy Chebon, Elina Asikanius, Gallia G. Levy

Blood (2017) 130 (Supplement 1): 1089.

https://doi.org/10.1182/blood.V130.Suppl_1.1089.1089

Published: 2017

Journal Articles

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors

Mark Crowther, MD, Gallia G. Levy, MD PhD, Genmin Lu, PhD, Janet Leeds, PhD, Joyce Lin, BS, Pratikhya Pratikhya, MS, Pamela B. Conley, PhD, Stuart Connolly, MD, John T. Curnutte, MDPhD

Blood (2014) 124 (21): 4269.

https://doi.org/10.1182/blood.V124.21.4269.4269

Published: 2014

Journal Articles

A Phase I Open-Label, Multi-Dose Escalation Study of the Dual Syk/Jak Inhibitor PRT062070 (Cerdulatinib) in Patients with Relapsed/Refractory B Cell Malignancies

Manish Patel, Paul Hamlin, MD, Donald K Strickland, MD, Anjali Pandey, PhD, Greg Coffey, PhD, Janet M Leeds, PhD, Gallia G. Levy, MD PhD, John T. Curnutte, MDPhD, Nina Wagner-Johnston, Ian W. Flinn, MD

Blood (2014) 124 (21): 3103.

https://doi.org/10.1182/blood.V124.21.3103.3103

Published: 2014

Journal Articles

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors

Crowther Mark, MD, Mathur Vandana, MD, Kitt Michael, MD, Lu Genmin, PhD, Pamela B. Conley, Ph.D., Hollenbach Stanley, JD, Janice Castillo, Athiwat Hutchaleelaha, Ph.D., Mark Karbarz, Ph.D., Joyce P. Lin, Lee Barron, PhD, Sandra Russell, R.N, Gallia G. Levy, MD, PhD, Stuart Connolly, M.D., John T. Curnutte, MD, PhD

Blood (2013) 122 (21): 3636.

https://doi.org/10.1182/blood.V122.21.3636.3636

Published: 2013

Journal Articles

Enhanced VWF biosynthesis and elevated plasma VWF due to a natural variant in the murine Vwf gene

Heidi L. Lemmerhirt, Jordan A. Shavit, Gallia G. Levy, Suzanne M. Cole, Jeffrey C. Long, David Ginsburg

Blood (2006) 108 (9): 3061–3067.

https://doi.org/10.1182/blood-2006-04-014688

Published: 2006

Includes: Supplemental data

Journal Articles

ADAMTS13 turns 3

Gallia G. Levy, David G. Motto, David Ginsburg

Blood (2005) 106 (1): 11–17.

https://doi.org/10.1182/blood-2004-10-4097

Published: 2005

NARROW

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3

Untreated Bleeds May Be Historically Under-Reported and More Prevalent in People with Hemophilia A with Inhibitors: An Examination of Bleed Data from a Prospective, Non-Interventional Study

Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia Α with Inhibitors: Results from the HAVEN 2 Study

HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors

Emicizumab Subcutaneous Dosing Every 4 Weeks for the Management of Hemophilia A: Preliminary Data from the Pharmacokinetic Run-in Cohort of a Multicenter, Open-Label, Phase 3 Study (HAVEN 4)

Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study

Bleeding Events and Safety Outcomes in Pediatric Persons with Hemophilia A with Inhibitors: The First Non-Interventional Study (NIS) from a Real-World Setting

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Edoxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), a Universal Antidote for Factor Xa (fXa) Inhibitors

A Phase I Open-Label, Multi-Dose Escalation Study of the Dual Syk/Jak Inhibitor PRT062070 (Cerdulatinib) in Patients with Relapsed/Refractory B Cell Malignancies

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors

Enhanced VWF biosynthesis and elevated plasma VWF due to a natural variant in the murine Vwf gene

ADAMTS13 turns 3

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only